FDA Panel Votes on BPC-157 and TB-500 Compounding: The July 2026 PCAC Outcome

The Pharmacy Compounding Advisory Committee (PCAC) is the outside panel of experts the FDA convenes to recommend which bulk drug substances licensed compounding pharmacies may prepare under Section 503A of the FD&C Act. On July 23 and 24, 2026, the committee met to vote on seven peptides for that list, and the outcome was closer, and more consequential for research suppliers, than most of the coverage headline suggests.

Editorial scope. Enlife Peptides supplies all products strictly for in-vitro laboratory research and does not sell compounded human drugs. This article summarizes a publicly reported FDA advisory committee vote as of July 26, 2026. Advisory committee votes are recommendations, not final agency action; verify current status against the FDA's own docket before making any compliance decision.

What the committee voted on

Seven peptides were on the agenda, split across the two meeting days.

Six of the seven passed. Only Emideltide, the FDA's regulatory name for Delta Sleep-Inducing Peptide (DSIP), was voted down.

This is a recommendation, not a rule change yet

A PCAC vote doesn't put anything on the compoundable-substances list by itself. Per compounding-law attorney Dustin Robinson, three separate legal events have to happen before a 503A pharmacy can actually prepare one of these peptides: removal from FDA's Category 2 restricted list, the PCAC recommendation (what just happened), and then formal notice-and-comment rulemaking to add the substance to the Category 1 compoundable list. That third step is the slow one, realistically running eight to twelve months. The FDA can also simply decline to act on a PCAC recommendation, though it rarely does.

For BPC-157, KPV, and TB-500 specifically, this vote builds on an earlier step: the FDA quietly removed KPV from Category 2 in April 2026, and HHS Secretary Robert F. Kennedy Jr. announced in February 2026 that roughly 14 peptides, including several on this list, would be reconsidered for a return to Category 1. This week's vote is the advisory-committee stage of that broader push, not its conclusion.

FDA's own scientists were opposed

Every outlet covering the meeting reported the same detail: FDA's career staff scientists unanimously recommended against adding any of the seven peptides to the compoundable list, citing a lack of controlled clinical trial data, inconsistent batch-to-batch manufacturing between compounding pharmacies, and the risk of immune reactions from impure or inconsistent peptide preparations. The committee voted to recommend six of the seven anyway. One member reportedly framed the tradeoff as a question of harm reduction, weighing the risk of an unregulated compounding pathway against pushing demand toward the unregulated gray market entirely.

Why Emideltide (DSIP) failed where the others passed

The committee's stated reasoning for rejecting Emideltide differed from the general evidence concerns raised about the other six. Coverage of the vote points to a specific gap: the clinical evidence supporting Emideltide's use leaned on a single-patient case report in narcolepsy, which several committee members apparently viewed as too thin a foundation even by the panel's own already-relaxed standard for this meeting.

What this means for BPC-157 and TB-500 right now

Nothing has changed in their legal status today. Both remain FDA Category 2, meaning 503A compounding pharmacies still cannot legally prepare them for individual-patient prescriptions while the rulemaking process plays out. Our BPC-157 FDA 2026 explainer and 2026 FDA peptide status tracker reflect the current, unchanged status and will be updated again if and when a proposed rule actually publishes.

For the research-use-only channel Enlife Peptides operates in, this vote doesn't change anything either. RUO material was never sold as a compounded prescription drug, and that distinction is unaffected by whether compounding pharmacies eventually gain a separate, prescription-based pathway for the same peptides.

Where the other four peptides stand

KPV, already out of Category 2 since April 2026, is the closest of the seven to an actual rule change. MOTS-c and Epitalon move from the general "not currently restricted" category toward a specific 503A bulks-list recommendation, worth watching if you follow our MOTS-c guide or Epitalon guide. Semax, covered in our Selank vs Semax comparison, picks up the same recommendation. DSIP, discussed in our sleep peptides overview, stays exactly where it was: not on any compounding list, and not currently recommended for one.

What happens next

Watch for the FDA's proposed rule in the Federal Register, the required public comment period, and a final rule, in that order. Given the eight-to-twelve month estimate reported by compounding-law counsel, a realistic earliest date for any of these six peptides to be legally compoundable under 503A is sometime in mid-to-late 2027, assuming the FDA moves forward at all. We'll update this article, rather than publish a separate post, as each stage lands.

Frequently Asked Questions

Does this vote mean BPC-157 is now legal for compounding pharmacies to prepare?

No. It's a recommendation to the FDA, not a rule change. BPC-157 remains FDA Category 2 today, and stays that way until the FDA completes formal rulemaking, a process estimated at eight to twelve months if it happens at all.

What is the 503A bulks list?

It's the FDA's list of bulk drug substances that licensed 503A compounding pharmacies may use to prepare custom prescription medications for individual patients. It's separate from FDA drug approval and separate from the research-use-only supply channel.

Why did Emideltide (DSIP) fail when six other peptides passed?

Committee members reportedly viewed its supporting clinical evidence, a single-patient narcolepsy case report, as weaker than the evidence base for the other six peptides, even though FDA staff scientists had opposed all seven.

Is the PCAC vote final?

No. It's a non-binding recommendation. The FDA can adopt it, modify it, or ignore it, and has gone against advisory committee recommendations before.

Does this change Enlife Peptides' research-use-only status or products?

No. Enlife Peptides sells peptides strictly for in-vitro laboratory research, not as compounded prescription drugs. A future compounding-pathway change for pharmacies doesn't alter that distinction.

Where can I verify this directly?

Start with the FDA's Pharmacy Compounding Advisory Committee meeting page for July 23-24, 2026, and the committee's posted briefing documents, both linked from FDA.gov's advisory committee calendar.

Related reading

• •BPC-157 FDA 2026: what the reclassification actually means
• •2026 FDA peptide status tracker
• •Is BPC-157 legal in 2026? Federal + state-by-state breakdown
• •BPC-157 vs TB-500: a research comparison
• •Research peptides vs. compounded prescription peptides: what changed in 2026

Sources and further reading

• •FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting calendar entry and briefing documents (FDA.gov)
• •STAT News, NBC News, ABC News, The Hill, U.S. News, and Pharmaceutical Executive coverage of the July 23-24, 2026 PCAC meeting

Editorial note & disclaimer. Reviewed by the Enlife Peptides research team. Informational only; not legal or medical advice. This article summarizes a developing regulatory story as of July 26, 2026, and will be updated as the rulemaking process advances. All peptides referenced are intended strictly for in-vitro laboratory research and are not approved by the FDA for human consumption or therapeutic use.